BACKGROUND AND OBJECTIVES: To evaluate the toxicity and efficacy of stereotactic body radiotherapy (SBRT) for the treatment of localized hepatocellular carcinoma (HCC) in the absence of another standard treatment option. METHODS: The authors reviewed the details of 38 patients with inoperable HCC (diameter <10 cm) treated by SBRT in a prospectively registered database at their institution. All patients had been treated by transcatheter arterial chemoembolization before SBRT, which had been finally deemed ineffective. SBRT dosages (33-57 Gy in three or four fractions) were administered according to tumor volumes, which ranged from 11 to 464 ml (median, 40.5 ml). RESULTS: Two-year overall survival and local progression-free survival rates were 61.4% and 66.4%, respectively. The local response rate was 63% at 3 months after SBRT. A high radiation dose was found to be independently related to survival. A decline in liver function was observed in six patients (16%) and Grade 3 musculoskeletal toxicity in one patient (2.7%). CONCLUSIONS: This study showed that SBRT can be safely administered to select HCC patients, and these results suggest that this technique should be considered a salvage treatment. A further well-controlled large-scale study and longer follow-up are needed to determine optimal dose-fraction schedules and characterize late complications. 2010 Wiley-Liss, Inc.
BACKGROUND AND OBJECTIVES: To evaluate the toxicity and efficacy of stereotactic body radiotherapy (SBRT) for the treatment of localized hepatocellular carcinoma (HCC) in the absence of another standard treatment option. METHODS: The authors reviewed the details of 38 patients with inoperable HCC (diameter <10 cm) treated by SBRT in a prospectively registered database at their institution. All patients had been treated by transcatheter arterial chemoembolization before SBRT, which had been finally deemed ineffective. SBRT dosages (33-57 Gy in three or four fractions) were administered according to tumor volumes, which ranged from 11 to 464 ml (median, 40.5 ml). RESULTS: Two-year overall survival and local progression-free survival rates were 61.4% and 66.4%, respectively. The local response rate was 63% at 3 months after SBRT. A high radiation dose was found to be independently related to survival. A decline in liver function was observed in six patients (16%) and Grade 3 musculoskeletal toxicity in one patient (2.7%). CONCLUSIONS: This study showed that SBRT can be safely administered to select HCC patients, and these results suggest that this technique should be considered a salvage treatment. A further well-controlled large-scale study and longer follow-up are needed to determine optimal dose-fraction schedules and characterize late complications. 2010 Wiley-Liss, Inc.
Authors: Sun Hyun Bae; Mi-Sook Kim; Won Il Jang; Chul-Seung Kay; Woochul Kim; Eun Seog Kim; Jin Ho Kim; Jin Hee Kim; Kwang Mo Yang; Kyu Chan Lee; A Ram Chang; Sunmi Jo Journal: Jpn J Clin Oncol Date: 2016-01-29 Impact factor: 3.019
Authors: Jennifer Pursley; Issam El Naqa; Nina N Sanford; Bridget Noe; Jennifer Y Wo; Christine E Eyler; Matthew Hwang; Kristy K Brock; Beow Y Yeap; John A Wolfgang; Theodore S Hong; Clemens Grassberger Journal: Int J Radiat Oncol Biol Phys Date: 2020-04-27 Impact factor: 7.038
Authors: Maria-Aggeliki Kalogeridi; Anna Zygogianni; George Kyrgias; John Kouvaris; Sofia Chatziioannou; Nikolaos Kelekis; Vassilis Kouloulias Journal: World J Hepatol Date: 2015-01-27